The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.
Delays in breast cancer presentation, diagnosis, and treatment in young women
Open accessAbstract
Background: Breast cancer (BC) in young patients is often identified at later stages, which can result in poor prognosis. It is important to investigate the factors influencing care delays and how delays affect outcomes. Methods: This study included women aged ≤40 years at diagnosis of stage 0–IV BC in the Young Women’s Breast Cancer Study enrolled between 2006 and 2016. Associations between patient and tumor factors and presentation delay (first symptom to provider visit, ≥90 days), diagnostic delay (presentation to diagnosis, ≥90 days), and treatment delay (diagnosis to treatment, ≥60 days) were estimated via logistic regression. Multivariable logistic models for delays were constructed via backward selection ( p ≤ .05 retained). Multivariable Cox proportional hazards models tested the association between delays and disease‐free survival (DFS) and overall survival (OS). Analyses were stratified by tumor subtype and stage. Results: Among 1071 women, there were 153 presentation, 120 diagnostic, and 228 treatment delays. In multivariable models, lower annual income was associated with higher odds of presentation delay, whereas pregnancy at diagnosis, family history of BC, and triple‐negative (TN) subtype were associated with lower odds. In HER2‐positive luminal B tumors, presentation delays were associated with later stage ( p < .001). Odds of diagnostic delay were higher for younger patients and lower for those with TN tumors. Patients with more aggressive tumor subtypes were less likely to have treatment delays. Delays were not associated with DFS or OS. Conclusions: In this cohort of young patients with BC, demographic and tumor factors were associated with delays in care. It is reassuring that delays did not influence disease outcomes.
Overview
CoChat Summary
TL;DR
In a prospective cohort of 1071 women aged ≤40 years with stage 0–IV breast cancer, 14% had presentation delay, 11% had diagnostic delay, and 22% had treatment delay. Delays were not independently associated with worse disease-free or overall survival, but presentation delay was linked to later stage in HER2-positive luminal B tumors.
Key findings
- Median times were 14 days (IQR, 2–45) from first symptom to presentation, 14 days (IQR, 7–30) from presentation to diagnosis, and 41 days (IQR, 25–57) from diagnosis to treatment. Presentation delay (≥90 days) occurred in 153 patients (14%), diagnostic delay (≥90 days) in 120 (11%), and treatment delay (≥60 days) in 228 stage 0–III patients (22%).
- In multivariable models, presentation delay was associated with income <$50,000 (OR, 1.98; 95% CI, 1.22–3.13) and inversely with pregnancy at diagnosis (OR, 0.17; 95% CI, 0.01–0.80), first-degree family history of breast cancer (OR, 0.40; 95% CI, 0.17–0.80), and TNBC versus luminal A (OR, 0.29; 95% CI, 0.13–0.60). Diagnostic delay was inversely associated with age (OR per year, 0.94; 95% CI, 0.90–0.99) and TNBC versus luminal A (OR, 0.35; 95% CI, 0.16–0.70). Treatment delay was inversely associated with TNBC versus luminal A (OR, 0.26; 95% CI, 0.14–0.45) and stage III versus stage I (OR, 0.36; 95% CI, 0.19–0.63).
- Presentation delay was associated with later stage at diagnosis among HER2-positive luminal B tumors (OR for stage III/IV vs. stage I/II, 3.19; 95% CI, 1.48–6.87; p < .001). Presentation and diagnostic delays were not significantly associated with DFS or OS; treatment delay was associated with longer DFS (unadjusted HR, 0.46; 95% CI, 0.30–0.71; fully adjusted HR, 0.51; 95% CI, 0.33–0.78) and longer OS in some models, but the OS association disappeared after adjustment for treatment and stage.
Methods
- Prospective cohort: Young Women’s Breast Cancer Study, 13 academic and community sites in the United States and Canada, enrolling women aged ≤40 years at diagnosis of stage 0–IV breast cancer between 2006 and 2016; 1071 of 1297 patients were included, with baseline surveys usually completed within 6 months of diagnosis (average 4 months from diagnosis).
- Exposures: patient-reported time from first symptom to provider visit (presentation delay ≥90 days), provider visit to diagnosis (diagnostic delay ≥90 days), and medical-record diagnosis to first treatment (surgery or chemotherapy, treatment delay ≥60 days). Univariable and multivariable logistic regression with backward selection (p ≤ .05 retained) assessed factors associated with delays; Cox proportional hazards models assessed DFS and OS, stratified by tumor subtype and stage, with mediation analysis.
- Survival analyses: DFS among 928 stage I–III patients over median follow-up of 12.3 years (IQR, 10.5–15.0); OS among 984 stage I–IV patients with 157 deaths. Treatment-delay models used left truncation from first treatment and adjusted for age, subtype, surgery, chemotherapy, radiation, and stage.
Limitations
- Stated in the paper: timing from symptom onset to presentation was patient-reported, with possible misclassification; the cohort was limited in racial, ethnic, and socioeconomic diversity, consisting mostly of White, insured patients with higher-than-average incomes; active research participants may have higher health-seeking behaviors than the general population.
- Stated in the paper: small numbers within subgroups limited some analyses; lack of gene expression data may limit histologic subtype classification; results were driven by patients with luminal-like disease, leaving questions for HR-negative/HER2-positive and TNBC patients; quality-of-life outcomes were not measured.
- Evident in the text: the observational design cannot establish causality; delay thresholds (≥90 or ≥60 days) are predefined cutoffs; residual confounding and limited subgroup power may affect the null survival findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 26 Not checked · 73 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specific delay types were not associated with survival in any individual tumor subtypes (Supporting Information S1: Table S7).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > OS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment delay was also less common for higher grade tumors (p = .03)(Table 3).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment delay was associated with longer DFS (unadjusted HR, 0.46; 95% CI, 0.30-0.71;p = .0003;fully adjusted HR, 0.51; 95% CI, 0.33-0.78;p = .002).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > DFS
plainstates an associationn = 928 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Presentation delay was associated with later stage at diagnosis among those with invasive HER2-positive luminal B tumors (OR for stage III and IV vs. stage I and II, 3.19; 95% CI, 1.48-6.87;p < .001).”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Presentation delay
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results were similar when including in situ (stage 0) patients.”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > DFS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
31 more claims
Create a free account to see all 99 claims and every source verdict.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Financial comfort Very comfortable 60 of 482 59 of 502 117 of 509 Less comfortable 156 of 487 1.64 (1.15-2.34).006”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
Reported 153 · recomputed 216
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Income ≥$50K 110 of 769 95 of 796 180 of 800 <$50K 122 of 157 1.72 (1.11-2.61).013”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
Reported 153 · recomputed 232
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Treatment delay
“First-degree family history of any cancer No 131 of 808 64 of 586 130 of 584”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Presentation delay
“First-degree family history of any cancer, No. (%) No 93 (8.7) Yes 918 (85.7)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Treatment delay (yes/no) b Crude 211 of 928 24 of 212 187 of 736 0.46 (0.30-0.71) .0003”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > DISCUSSION
Reported 928 · recomputed 948
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Study population
“HER2-positive luminal B (HR-positive, HER2-negative)”
§ Delays in breast cancer presentation, diagnosis, and treatment in young women > Presentation delay
“HER2+ luminal B (HR+, HER2+) 206 (19.2)”
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationTime to Surgery and Breast Cancer Survival in the United States
Bleicher, R. J., Ruth, K., Sigurdson, E. R., Beck, J. R., Ross, E., Wong, Y.-N., Patel, S. A., Boraas, M., Chang, E. I., Topham, N. S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4508 · Cited by 609
Hispanic health in the USA: a scoping review of the literature
Velasco-Mondragon, E., Jimenez, A., Palladino-Davis, A. G., Davis, D., & Escamilla-Cejudo, J. A. (2016) · Public Health Reviews · doi:10.1186/s40985-016-0043-2 · Cited by 514
Factors predicting delayed presentation of symptomatic breast cancer: a systematic review
Ramirez, A., Westcombe, A., Burgess, C., Sutton, S., Littlejohns, P., & Richards, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02142-x · Cited by 493
Biology of breast cancer in young women
Azim, H. A., & Partridge, A. H. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0427-5 · Cited by 466
Self-citationGlobal guidelines for breast cancer screening: A systematic review
Ren, W., Chen, M., Qiao, Y., & Zhao, F. (2022) · The Breast · doi:10.1016/j.breast.2022.04.003 · Cited by 325
Delay in Breast Cancer: Implications for Stage at Diagnosis and Survival
Caplan, L. S. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00087 · Cited by 320
Delays in Breast Cancer Diagnosis and Treatment by Racial/Ethnic Group
Gorin, S. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.20.2244 · Cited by 294
Smith, E. C., Ziogas, A., & Anton-Culver, H. (2013) · JAMA Surgery · doi:10.1001/jamasurg.2013.1680 · Cited by 276
Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002158 · Cited by 258
Narod, S. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.102 · Cited by 254
Breast cancer in adolescents and young adults
Johnson, R. H., Anders, C. K., Litton, J. K., Ruddy, K. J., & Bleyer, A. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27397 · Cited by 237
Self-citationMcLaughlin, J. M., Anderson, R. T., Ferketich, A. K., Seiber, E. E., Balkrishnan, R., & Paskett, E. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.39.7695 · Cited by 213
Koo, M. M., von Wagner, C., Abel, G. A., McPhail, S., Rubin, G. P., & Lyratzopoulos, G. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2017.04.010 · Cited by 186
Fedewa, S. A., Ward, E. M., Stewart, A. K., & Edge, S. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2427 · Cited by 164
Health system delay and its effect on clinical stage of breast cancer: Multicenter study
Unger‐Saldaña, K., Miranda, A., Zarco‐Espinosa, G., Mainero‐Ratchelous, F., Bargalló‐Rocha, E., & Lázaro-León, J. M. (2015) · Cancer · doi:10.1002/cncr.29331 · Cited by 137
The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer
Partridge, A. H., Hughes, M. E., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0469 · Cited by 135
Self-citationBreast cancer presentation and diagnostic delays in young women
Ruddy, K. J., Gelber, S., Tamimi, R. M., Schapira, L., Come, S. E., Meyer, M. E., Winer, E. P., & Partridge, A. H. (2014) · Cancer · doi:10.1002/cncr.28287 · Cited by 116
Self-citationTriple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes
Billar, J. A. Y., Dueck, A. C., Stucky, C.-C., Gray, R. J., Wasif, N., Northfelt, D., McCullough, A. E., & Pockaj, B. A. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1260-4 · Cited by 95
Cohen, M. W. (2005) · Psycho-Oncology · doi:10.1002/pon.1018 · Cited by 94
Misconceptions about Breast Lumps and Delayed Medical Presentation in Urban Breast Cancer Patients
Rauscher, G. H., Ferrans, C. E., Kaiser, K., Campbell, R. T., Calhoun, E., & Warnecke, R. B. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0997 · Cited by 93
Smith, B. L., Gadd, M. A., Lawler, C., MacDonald, D. J., Grudberg, S. C., Chi, F. S., Carlson, K., Comegno, A., & Souba, W. W. (1996) · Surgery · doi:10.1016/s0039-6060(96)80301-1 · Cited by 84
Lawson, M. B., Bissell, M. C. S., Miglioretti, D. L., Eavey, J., Chapman, C. H., Mandelblatt, J. S., Onega, T., Henderson, L. M., Rauscher, G. H., Kerlikowske, K. M., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1990 · Cited by 84
Kupstas, A. R., Hoskin, T. L., Day, C. N., Habermann, E. B., & Boughey, J. C. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07566-7 · Cited by 70
Racial Disparities in Diagnostic Delay Among Women With Breast Cancer
Miller‐Kleinhenz, J. M., Collin, L. J., Seidel, R. L., Reddy, A., Nash, R., Switchenko, J. M., & McCullough, L. E. (2021) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2021.06.019 · Cited by 70
Khan, M. A., Hanif, S., Iqbal, S., Shahzad, M. F., Shafique, S., & Khan, M. T. (2015) · Chinese Journal of Cancer Research · doi:10.3978/j.issn.1000-9604.2015.04.11 · Cited by 67
Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile
Jaiswal, K. R., Hull, M. L., Furniss, A., Doyle, R., Gayou, N., & Bayliss, E. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7067 · Cited by 64
The effect of delays in treatment for breast cancer metastasis on survival
Jung, S. Y., Sereika, S. M., Linkov, F. Y., Brufsky, A., Weissfeld, J. L., & Rosenzweig, M. Q. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1662-4 · Cited by 63
Unger‐Saldaña, K., Ventosa‐Santaulària, D., Miranda, A., & Verduzco-Bustos, G. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0431 · Cited by 59
Relationship between insurance status and outcomes for patients with breast cancer in Missouri
Berrian, J. L., Liu, Y., Lian, M., Schmaltz, C., & Colditz, G. A. (2020) · Cancer · doi:10.1002/cncr.33330 · Cited by 58
Foroozani, E., Ghiasvand, R., Mohammadianpanah, Μ., Afrashteh, S., Bastam, D., Kashefi, F., Shakarami, S., & Dianatinasab, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-78517-6 · Cited by 58
Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers
Costa, L., Kumar, R., Villarreal-Garza, C. M., Sinha, S., Saini, S., Semwal, J., Saxsena, V., Zamre, V., Chintamani, C., Ray, M. D., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.103623 · Cited by 58
Petrova, D., Garrido, D., Špacírová, Z., Fernández‐Martínez, N. F., Ivanova, G., Rodríguez‐Barranco, M., Pollán, M., Barrios‐Rodríguez, R., & Sánchez, M. (2022) · Psycho-Oncology · doi:10.1002/pon.6064 · Cited by 45
Young people describe their prediagnosis cancer experience
Gibson, F., Pearce, S., Eden, T. O. B., Glaser, A., Hooker, L., Whelan, J., & Kelly, D. M. (2013) · Psycho-Oncology · doi:10.1002/pon.3325 · Cited by 43
Identifying predictors of delayed diagnoses in symptomatic breast cancer: a scoping review
Webber, C., Jiang, L., Grunfeld, E., & Groome, P. A. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12483 · Cited by 43
Identifying Women at Risk of Delayed Breast Cancer Diagnosis
Stuver, S. O., Zhu, J., Simchowitz, B., Hassett, M. J., Shulman, L. N., & Weingart, S. N. (2011) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(11)37073-0 · Cited by 40
Young adults' experiences with cancer: comments from patients and survivors.
Miedema, B. B., Easley, J., & Hamilton, R. A. (2006) · Europe PMC (PubMed Central) · Cited by 36
Family History of Breast Cancer: Impact on the Disease Experience
Petrisek, A. C., Campbell, S. E., & Laliberte, L. L. (2000) · Cancer Practice · doi:10.1046/j.1523-5394.2000.83007.x · Cited by 35
Ramírez, A. G., Pérez‐Stable, E. J., Talavera, G. A., Penedo, F. J., Carrillo, J. E., Fernández, M. E., Muñoz, E., Parma, D. L., Holden, A. E. C., Miguel, S. S., et al. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-84 · Cited by 31
Diagnostic delay in women with cancer: What do we know and which factors contribute?
Hoveling, L. A., Schuurman, M. S., Siesling, S., van Asselt, K. M., & Bode, C. (2025) · The Breast · doi:10.1016/j.breast.2025.104427 · Cited by 30
Ungvari, Z. I., Fekete, M., Buda, A., Lehoczki, A., Munkácsy, G., Scaffidi, P., Bonaldi, T., Fekete, J. T., Bianchini, G., Varga, P., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01719-1 · Cited by 29
Cancer biology may be more important than diagnostic delay
Symonds, R. P. (2002) · BMJ · doi:10.1136/bmj.325.7367.774 · Cited by 28
Sociodemographic Factors Associated with Delays in Breast Cancer
Guèye, M., Gueye, S. M. K., Diallo, M., Thiam, O., Mbodji, A., Diouf, A., Fall, K. A. M., Toure, Y., Daff, H. M. B., & Moreau, J. C. (2017) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2017.74047 · Cited by 26
Disparities in timely treatment among young women with breast cancer
Jain, U., Jain, B., Fayanju, O. M., Chino, F. L., & Dee, E. C. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.01.019 · Cited by 25
Delayed breast cancer presentation, diagnosis, and treatment in Kenya
Ojuka, D. K., Ashrafi, A., Musibi, A., Njoki, N., Eric, H., Omondi, M., Aseta, F. B., Beth, W. G., Nyakio, M., Odero‐Marah, V., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07067-y · Cited by 24
Rosenberg, S. M., Zheng, Y. H., Ruddy, K. J., Poorvu, P. D., Snow, C., Kirkner, G. J., Meyer, M. E., Tamimi, R. M., Schapira, L., Peppercorn, J. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081157 · Cited by 22
Self-citationHumlevik, R. O. C., Svanøe, A. A., Aas, T., Heie, A., Sæle, A. K. M., Akslen, L. A., Wik, E., & Høivik, E. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-90053-9 · Cited by 21
Factors Mediating Racial/Ethnic Disparities in Delayed Treatment of Breast Cancer
Schermerhorn, M. C., Grunvald, M. W., O’Donoghue, C., Rao, R. D., & Becerra, A. Z. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12001-5 · Cited by 19
Ferdause, J., Ahmed, N., Rahman, L., Aain, K. R. R., Ferdausi, F. A., Kadir, A. K. M. S., & Haque, M. A. (2025) · Medicine · doi:10.1097/md.0000000000041775 · Cited by 19
Cancer awareness among adolescents in second-level education: a mixed methods systematic review
Lawrence, S. M., Fitzgerald, S. M., Hegarty, J. M., & Saab, M. M. (2025) · Health Education Research · doi:10.1093/her/cyaf014 · Cited by 18
Does a positive family history influence the presentation of breast cancer?
Yip, C. H., Taib, N. A. M., & Lau, P. C. (2008) · PubMed · Cited by 17
Kehm, R. D., Daaboul, J. M., Tehranifar, P., & Terry, M. B. (2025) · Cancer Causes & Control · doi:10.1007/s10552-025-01968-7 · Cited by 17
Treatment cost and access to care: experiences of young women diagnosed with breast cancer
Subramanian, S., Tangka, F. K. L., Edwards, P., Jones, M., Flanigan, T., Kaganova, J., Smith, K. W., Thomas, C. C., Hawkins, N. A., Rodriguez, J. L., et al. (2020) · Cancer Causes & Control · doi:10.1007/s10552-020-01334-9 · Cited by 14
Change in Breast Cancer Screening Intervals Since the 2009 USPSTF Guideline
Wernli, K. J., Arao, R. F., Hubbard, R. A., Sprague, B. L., Alford‐Teaster, J., Haas, J. S., Henderson, L. M., Hill, D., Lee, C. I., Tosteson, A. N. A., et al. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.6076 · Cited by 13
Dunn, M. R., Li, D., Emerson, M. A., Thompson, C. A., Nichols, H. B., Alsten, S. C. V., Roberson, M. L., Wheeler, S. B., Carey, L., Hyslop, T., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004500 · Cited by 12
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil
Shafaee, M. N., da Silva, L. R., Ramalho, S., Dória, M. T., Natal, R. D. A., Cabello, V., Cons, L., Pavanello, M., Zeferino, L. C., Mano, M. S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac050 · Cited by 11
Erdogan, E., & Tuzcu, A. (2020) · Women & Health · doi:10.1080/03630242.2020.1746949 · Cited by 10
Breast cancer treatment delay and the Hispanic paradox: A SEER database analysis
Roldan‐Vasquez, E., Mitri, S., Brantley, K. D., James, T. A., & Schlam, I. M. (2024) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2024.116135 · Cited by 9
Self-citationMartín‐García, D., García‐Aranda, M., Moreno, E. V., Padilla-Ruiz, M., Zarcos‐Pedrinaci, I., Rivas‐Ruiz, F., Téllez, T., García‐Gutiérrez, S., González, N., Rivero‐Santana, A., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110280 · Cited by 5
Yoon, I. C., Perez-Rojas, S., Ancha, B., Elmore, L. C., Mateo, A. M., Pichardo, M. S., Tchou, J. C., Zhang, J. Q., Hubbard, R. A., & Fayanju, O. M. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17367-w · Cited by 4
Cakmak, G. K., Tali, U., Balbaloĝlu, H., Taşdöven, İ., Özkurt, E., Karanlık, H., Zihni, İ., Doğan, L., Akçay, M. N., Günay, S., et al. (2025) · European Journal of Public Health · doi:10.1093/eurpub/ckaf108 · Cited by 4
Beauchemin, M., Wooster, M. E., DeStephano, D. M., Harkins, S., Wang, S., Wright, J. D., Kahn, J. M., Accordino, M. K., & Hershman, D. L. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.16_suppl.11091 · Cited by 1
Cited by
Still being checked.
Metadata
- Authors
- Zhang, B. X., Sella, T., Zheng, Y., Kirkner, G. J., Ruddy, K. J., Rosenberg, S. M., Borges, V. F., Schapira, L., Come, S. E., Peppercorn, J. M., Collins, L., Partridge, A. H., & Brantley, K. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- University of Colorado Cancer Center (US)
- Stanford Medicine (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Brantley, Kristen D.
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2026-10-12
- Volume
- 132
- Issue
- 20
- Pages
- e70594-e70594
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W7221518840
- Cited by
- 0
- References
- 63
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- breast cancer, young women, delayed care, delayed presentation, delayed diagnosis, treatment delay, triple-negative breast cancer, tumor subtypes, family history of breast cancer, income, disease-free survival, overall survival
- MeSH terms
- Treatment Delay, Adult, Breast Neoplasms, Female, Humans, Neoplasm Staging, Prognosis, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Young Adult, Delayed Diagnosis, Time-to-Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.